Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01AUL
|
|||
| Former ID |
DIB001245
|
|||
| Drug Name |
L-697639
|
|||
| Synonyms |
HND0YP0TJG; 135525-77-8; UNII-HND0YP0TJG; L 697639; L-697,639; L-697639; 3-[(4,7-dimethyl-1,3-benzoxazol-2-yl)methylamino]-5-ethyl-6-methyl-1H-pyridin-2-one; 2(1H)-Pyridinone,3-[[(4,7-dimethyl-2-benzoxazolyl) methyl]amino]-5-ethyl-6-methyl-; DRG-0101; ACMC-20mvsl; 3benzoxazolMeNH deriv.; AC1L1U0H; CHEMBL37803; SCHEMBL6367001; BDBM1314; AC1Q69B1; CTK4B9862; DTXSID50159456; VDZJXIOFISBBLT-UHFFFAOYSA-N; 3-(((4,7-Dimethyl-1,3-benzoxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Discontinued in Phase 1 | [1] | |
| Company |
Merck & Co Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21N3O2
|
|||
| Canonical SMILES |
CCC1=C(NC(=O)C(=C1)NCC2=NC3=C(C=CC(=C3O2)C)C)C
|
|||
| InChI |
1S/C18H21N3O2/c1-5-13-8-14(18(22)20-12(13)4)19-9-15-21-16-10(2)6-7-11(3)17(16)23-15/h6-8,19H,5,9H2,1-4H3,(H,20,22)
|
|||
| InChIKey |
VDZJXIOFISBBLT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 135525-77-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002199) | |||
| REF 2 | Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor. Int J Clin Pharmacol Res. 1994;14(2):45-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.